CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity (CURES)
Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery
Sponsor: Merck Sharp & Dohme LLC
This PHASE4 trial investigates Cerebral Tissue Oxygenation and Laparoscopic Gastric Bypass Surgery and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jun 2022 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Ziekenhuis Oost-Limburg
For direct contact, visit the study record on ClinicalTrials.gov .